Entry Point Capital, LLC Cogent Biosciences, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 52,346 shares of COGT stock, worth $433,424. This represents 0.18% of its overall portfolio holdings.
Number of Shares
52,346Holding current value
$433,424% of portfolio
0.18%Shares
3 transactions
Others Institutions Holding COGT
# of Institutions
178Shares Held
114MCall Options Held
56.7KPut Options Held
40.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$86.7 Million0.31% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.24MShares$76.5 Million8.19% of portfolio
-
Commodore Capital LP New York, NY7.54MShares$62.4 Million6.92% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$60.3 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$57.7 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $544M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...